These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 9096609

  • 21. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
    Ioriya K, Kino K, Horisawa S, Nishimura T, Muraoka M, Noguchi T, Ohashi N.
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
    [Abstract] [Full Text] [Related]

  • 22. Regulation of lymphocyte proliferation by cholesterol: the role of endogenous sterol metabolism and low density lipoprotein receptors.
    Cuthbert JA, Lipsky PE.
    Int J Tissue React; 1987 Feb; 9(6):447-57. PubMed ID: 3448024
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
    Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H.
    Cancer Res; 2001 Jun 15; 61(12):4885-91. PubMed ID: 11406567
    [Abstract] [Full Text] [Related]

  • 24. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
    Song CY, Kim BC, Lee HS.
    Transl Res; 2008 Jan 15; 151(1):27-35. PubMed ID: 18061125
    [Abstract] [Full Text] [Related]

  • 25. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW.
    Metabolism; 2001 Oct 15; 50(10):1234-41. PubMed ID: 11586500
    [Abstract] [Full Text] [Related]

  • 26. Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
    Nguyen LB, Salen G, Shefer S, Tint GS, Ruiz F.
    Metabolism; 2001 Oct 15; 50(10):1224-9. PubMed ID: 11586498
    [Abstract] [Full Text] [Related]

  • 27. Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
    Messa C, Notarnicola M, Russo F, Cavallini A, Pallottini V, Trentalance A, Bifulco M, Laezza C, Gabriella Caruso M.
    Scand J Gastroenterol; 2005 Dec 15; 40(12):1454-61. PubMed ID: 16293557
    [Abstract] [Full Text] [Related]

  • 28. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
    Connelly-Smith L, Pattinson J, Grundy M, Shang S, Seedhouse C, Russell N, Pallis M.
    Exp Hematol; 2007 Dec 15; 35(12):1793-800. PubMed ID: 17923246
    [Abstract] [Full Text] [Related]

  • 29. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R.
    Rev Esp Cardiol; 1995 Jan 15; 48(1):59-65. PubMed ID: 7878284
    [No Abstract] [Full Text] [Related]

  • 30. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
    Suárez Y, Fernández C, Gómez-Coronado D, Ferruelo AJ, Dávalos A, Martínez-Botas J, Lasunción MA.
    Cardiovasc Res; 2004 Nov 01; 64(2):346-55. PubMed ID: 15485695
    [Abstract] [Full Text] [Related]

  • 31. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K, Kurokawa J, Nomura S, Kuga Y, Ohkura Y, Kajiyama G.
    Biochim Biophys Acta; 1993 Apr 07; 1167(2):223-5. PubMed ID: 8466953
    [Abstract] [Full Text] [Related]

  • 32. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E, Watanabe I, Nagao K, Kanmatsuse K.
    J Cardiol; 2000 Apr 07; 35(4):277-85. PubMed ID: 10791271
    [Abstract] [Full Text] [Related]

  • 33. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
    Kim CH, Kim HJ, Mitsuhashi M, Vaziri ND.
    Metabolism; 2007 Oct 07; 56(10):1377-82. PubMed ID: 17884448
    [Abstract] [Full Text] [Related]

  • 34. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
    Honda A, Salen G, Nguyen LB, Xu G, Tint GS, Batta AK, Shefer S.
    Hepatology; 1998 Jan 07; 27(1):154-9. PubMed ID: 9425931
    [Abstract] [Full Text] [Related]

  • 35. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells.
    Yanagita T, Yamamoto K, Ishida S, Sonda K, Morito F, Saku K, Sakai T.
    Clin Ther; 1994 Jan 07; 16(2):200-8. PubMed ID: 8062316
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells.
    Al Rayyes O, Ahrén B, Florén CH.
    Eur J Pharmacol; 1999 May 21; 372(3):311-8. PubMed ID: 10395027
    [Abstract] [Full Text] [Related]

  • 37. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity is inhibited by cholesterol and up-regulated by sitosterol in sitosterolemic fibroblasts.
    Honda A, Salen G, Honda M, Batta AK, Tint GS, Xu G, Chen TS, Tanaka N, Shefer S.
    J Lab Clin Med; 2000 Feb 21; 135(2):174-9. PubMed ID: 10695663
    [Abstract] [Full Text] [Related]

  • 38. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
    Yu YH, Wang Y, Dong B, Sun SZ, Chen Y, Meng XH, Liu ZZ.
    Chin Med J (Engl); 2005 Apr 20; 118(8):621-6. PubMed ID: 15899115
    [Abstract] [Full Text] [Related]

  • 39. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
    Pedreño J, Sánchez JL, Zambón D, Ros E.
    Coron Artery Dis; 1994 Dec 20; 5(12):971-7. PubMed ID: 7728297
    [Abstract] [Full Text] [Related]

  • 40. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages.
    Bernini F, Scurati N, Bonfadini G, Fumagalli R.
    Arterioscler Thromb Vasc Biol; 1995 Sep 20; 15(9):1352-8. PubMed ID: 7670949
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.